エプスタイン・バー・ウイルス(EBV)による劇症肝不全:免疫不全疾患における症例報告
Diana Coman1, Julian Hercun1, Daniel Corsilli2
1Liver Unit, Centre hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.
Canadian liver journal
|February 23, 2026
まとめ
エプスタイン・バー・ウイルス(EBV)肝炎は通常軽症であるが、特にX連鎖リンパ増殖性疾患のような免疫不全症では、まれに致命的となることがある。重症肝障害には、迅速な集学的治療が不可欠である。
科学分野:
- 肝臓学
- ウイルス学
- 免疫学
背景:
- エプスタイン・バー・ウイルス(EBV)は一般的に肝炎を引き起こし、通常は自然に治癒する。
- 特に免疫不全者においては、重篤な転帰または死亡に至ることがある。
研究 の 目的:
- 急性EBV肝炎の2つの異なる症例を報告する。
- EBV肝炎の多様な臨床像と予後を強調する。
主な方法:
- 単一施設での症例シリーズアプローチを用いた。
- 臨床データおよび死後所見を分析した。
主要な成果:
- 一人の患者は劇症肝炎、多臓器不全、免疫調節不全を経験し、最終的に死亡した。死後検査により、原発性免疫不全症であるX連鎖リンパ増殖性疾患(XLP)が明らかになった。二番目の患者は、持続的なEBVウイルス血症に関連する肝炎、細胞減少症、肝脾腫を呈し、デキサメタゾンおよびリツキシマブを含む治療に良好に反応した。
- 一人の患者は劇症肝炎、多臓器不全、免疫調節不全を経験し、最終的に死亡した。死後検査により、原発性免疫不全症であるX連鎖リンパ増殖性疾患(XLP)が明らかになった。二番目の患者は、持続的なEBVウイルス血症に関連する肝炎、細胞減少症、肝脾腫を呈し、デキサメタゾンおよびリツキシマブを含む治療に良好に反応した。
結論:
- 重症のEBV関連肝障害には、迅速かつ集学的な管理が必要である。
- XLPは、重症EBV肝炎および関連合併症の重要な危険因子である。
関連する概念動画
Immunodeficiency Diseases
2.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.6K
Pulmonary Tuberculosis I
1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
273
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
273


